Explore Business Standard
Pharma major Lupin Ltd on Monday said it has signed a license and supply agreement with China's Sino Universal Pharmaceuticals for the commercialisation of Tiotropium dry powder inhaler in the Chinese market. The agreement pertains to the commercialisation of the Tiotropium dry powder inhaler of strength 18 mcg/capsule, which is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD), Lupin said in a regulatory filing. Under the agreement, Sino Universal Pharmaceuticals (SUP) will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorisation holder and responsible for manufacturing of the product, it added. "This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector," Lupin President Corporate Development, Fabrice Egros said. With SUP, the company aim to enhance patient acces
High blood pressure impairs one's breathing capacity by hardening the airways in the respiratory system, thereby increasing resistance, a study has found. However, being physically active can help by improving the functioning of respiratory muscles, resulting in better coordination between ventilation and blood flow in the lungs, researchers from the Federal University of Sao Paulo, Brazil, found. Hypertension, in which one's blood pressure remains unusually high, is known to thicken the blood vessels and harden the arteries. The researchers said that something similar happens with the bronchi -- branches of the main windpipe (trachea) -- in the respiratory system as well. "This is very important as the more hardened the bronchi becomes, the more difficult it becomes for air to enter and leave the lungs. In the long run, this accelerated process of hardening of the bronchi makes breathing difficult for older people. Worse still, it's a cycle: lower oxygen saturation accelerates the
Rise in air pollution is linked to growing respiratory ailments in India, experts have said and urged the government to bring a policy limiting the number of cars per family and restricting the number of vehicles plying on roads at a time. On the sidelines of the 25th National Conference on Pulmonary Diseases (NAPCON-2023), organised by the Indian Chest Society here, Dr Rakesh K Chawla, the chairman of Pulmonology and Critical Care at Jaipur Golden Hospital, said air pollution has short-term as well as long-term effects on health. "The immediate effects are in the form of irritation in the eyes and throat. Also, there is an increase in the severity of asthma attacks," said Dr Chawla, who is also the organising chairman of NAPCON-2023. The conference was organised to discuss air pollution and diseases caused by it as well as the advancements in the field of pulmonology. Dr Chawla said the long-term effects of air pollution include respiratory diseases and lung cancer, and the worst
Up to 11 per cent of Covid cases that needed hospitalisation had lung scarring which may be irreversible and could get worse over time, according to a study conducted in the United States. The study, published in the American Journal of Respiratory and Critical Care Medicine, sought to determine the percentage of COVID-19 patients, with various degrees of severity, discharged from hospital who had a type of fibrotic lung damage, known as interstitial lung disease, that requires follow-up care. Interstitial lung disease refers to a broad group of diseases that are characterized by lung scarring, including idiopathic lung fibrosis. This scarring makes it difficult to breathe and get oxygen into the bloodstream. Lung damage caused by this may be irreversible and get worse over time. "We estimated that up to 11 per cent of hospitalised Covid patients had fibrotic patterning after recovery from the acute illness," said corresponding author Iain Stewart, an advanced research fellow (Rayne
Alembic Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial, the company said in a statement. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD), Brovana inhalation solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc, it added. Arformoterol Tartrate inhalation solution is indicated for long-term, twice daily administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the company said. This ANDA has ...